ECSP982756A - HYDROXAMIC ACID DERIVATIVES AS MATRIX METALPROTEASE INHIBITORS (MMP) - Google Patents
HYDROXAMIC ACID DERIVATIVES AS MATRIX METALPROTEASE INHIBITORS (MMP)Info
- Publication number
- ECSP982756A ECSP982756A ECSP982756A ECSP982756A EC SP982756 A ECSP982756 A EC SP982756A EC SP982756 A ECSP982756 A EC SP982756A EC SP982756 A ECSP982756 A EC SP982756A
- Authority
- EC
- Ecuador
- Prior art keywords
- hydrogen
- alkyl
- mmp
- inhibitors
- acid derivatives
- Prior art date
Links
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000011159 matrix material Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 229940124761 MMP inhibitor Drugs 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
- 230000037314 wound repair Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Los compuestos de fórmula (I), las sales farmacéutica y veterinariamente aceptables de los mismos, o los solvatos farmacéutica o veterinariamente aceptables de cualquiera de las dos entidades, en la que la línea a trazos representa un enlace opcional; A es C o CH; B es CH2 O o esta ausente; cada uno de R1 y R2 se selecciona, independientemente, entre hidrógeno, alquilo C1-C6 opcionalmente sustituido con alcoxi C1 a C4 o fenilo, y alquenilo C1 a C6; o junto con el átomo de carbono al que están unidos, forman un grupo cicloalquilo C3 a C6 que incorpora opcionalmente un enlace con un heteroátomo seleccionado entre O, SO, SO2 y NR6 que esta opcionalmente condensado con benceno; R3 es hidrógeno, halo R7 u OR7; R4 es hidrógeno, alquilo C1 a C4 alcoxi C1 a C4, trifluorometilo o halo; R6 es hidrógeno o alquilo C1 a C4, R7 es un sistema de anillo monocíclico bicíclico; m es 1 ó 2; y n es 0, 1, ó 2; con la condición de que B no sea O cuando A es C; son inhibidores de MMp útiles en el tratamiento de, entre otras enfermedades, la ulceración de tejidos, la reparación de heridas y las enfermedades cutáneas.The compounds of formula (I), the pharmaceutically and veterinarily acceptable salts thereof, or the pharmaceutically or veterinarily acceptable solvates of either entity, wherein the dashed line represents an optional bond; A is C or CH; B is CH2 O or is absent; R1 and R2 are each independently selected from hydrogen, C1-C6 alkyl optionally substituted with C1 to C4 alkoxy or phenyl, and C1 to C6 alkenyl; or together with the carbon atom to which they are attached, they form a C3 to C6 cycloalkyl group optionally incorporating a bond with a heteroatom selected from O, SO, SO2 and NR6 that is optionally fused with benzene; R3 is hydrogen, halo R7 or OR7; R4 is hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, trifluoromethyl or halo; R6 is hydrogen or C1 to C4 alkyl, R7 is a bicyclic monocyclic ring system; m is 1 or 2; and n is 0, 1, or 2; with the proviso that B is not O when A is C; they are MMp inhibitors useful in the treatment of, among other diseases, tissue ulceration, wound repair and skin diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982756 ECSP982756A (en) | 1998-11-26 | 1998-11-26 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALPROTEASE INHIBITORS (MMP) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982756 ECSP982756A (en) | 1998-11-26 | 1998-11-26 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALPROTEASE INHIBITORS (MMP) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP982756A true ECSP982756A (en) | 1999-05-06 |
Family
ID=42043675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP982756 ECSP982756A (en) | 1998-11-26 | 1998-11-26 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALPROTEASE INHIBITORS (MMP) |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP982756A (en) |
-
1998
- 1998-11-26 EC ECSP982756 patent/ECSP982756A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8463501A1 (en) | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALOPROTEASE INHIBITORS (MMP) | |
| ES2061480T3 (en) | ARYLOXY- AND ARYLACILOXI-METHYL KETHONES INHIBITING THIOL PROTEASES. | |
| HUP0002092A2 (en) | N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | |
| ES2184280T3 (en) | INDOL COMPOUNDS AS COX-2 'INHIBITORS. | |
| AR039226A2 (en) | USEFUL COMPOUNDS AS PREPARATION INTERMEDIARIES AND PROCEDURES | |
| CO4960662A1 (en) | CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND THEIR DERIVATIVES | |
| ATE282614T1 (en) | PHENYL UREA AND PHENYLTHIOUREA DERIVATIVES | |
| CO4440628A1 (en) | PIRIMIDINE DERIVATIVES CONDENSED WITH A HETERO-CYCLIC RING | |
| ES2108855T3 (en) | DERIVATIVES OF OXAMIC ACID AS HYPOCHOLESTEREMIC AGENTS. | |
| MX9206939A (en) | DERIVATIVES OF PIPERAZINE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM | |
| PT887344E (en) | QUINOLINS AND UTIAL CHINAZOLINS IN THERAPY | |
| AR018859A1 (en) | A COMPOUND DERIVED FROM INDOL, AND A PHARMACEUTICAL FORMULATION THAT UNDERSTANDS | |
| ES2123652T3 (en) | 7- (2-AMINOETIL) -BENZOTIAZOLONAS. | |
| NO952208D0 (en) | The amine derivatives | |
| PE20040907A1 (en) | ANILINOPYRAZOLE DERIVATIVES | |
| ES2059828T3 (en) | A PROCEDURE FOR THE PREPARATION OF A COMPOUND. | |
| DK269083A (en) | HYDROXYALKYNYL-AZOLYL DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | |
| DK0526313T3 (en) | New urea derivatives, their preparation and therapeutic use | |
| ES2155660T3 (en) | DERIVATIVES OF BENCIMIDAZOL, BENZOXAZOL AND BENZOTIAZOL, USED AS INHIBITORS OF INTERLEUQUINA 1BETA. | |
| DK327286D0 (en) | INDOLCARBOXAMIDE DERIVATIVES AND SALTS THEREOF, THEIR PREPARATION AND USE AS MEDICINAL PRODUCTS AND INTERMEDIATES FOR THEIR PREPARATION | |
| ES515904A0 (en) | "PROCEDURE TO PREPARE NEW TRIAZOLOQUINAZOLONAS". | |
| ECSP982756A (en) | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALPROTEASE INHIBITORS (MMP) | |
| NO925058L (en) | Tissue Protective Tocopherol Analogs | |
| DK349287D0 (en) | (2-DIMETHYLAMINO-ETHYL) (2 - ((2-METHYLTHIO-PHENYL) (PHENYLMETHYL) AMINO) -2-OXO-ETHYL) CARBAMATES OR URINARY SUBSTANCES, PREPARATION FOR PRODUCTION AND PREPARATION FOR PREPARATION AND PREPARATION | |
| MX9302165A (en) | BENZOXAZINONE AND BENZOTHIAZINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS WHICH INCLUDE THEM |